Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 165

Results For "data"

1815 News Found

HCL Tech and Innovaccer collaborate to scale up digital health transformation
Digitisation | October 20, 2021

HCL Tech and Innovaccer collaborate to scale up digital health transformation

By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance


NIH grants in-principle accreditation to Advanced Enzymes supplements
Healthcare | October 20, 2021

NIH grants in-principle accreditation to Advanced Enzymes supplements

The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness


Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %
Biotech | October 19, 2021

Vertex’s stem cell therapy for Type 1 diabetes reduced daily insulin requirement by 91 %

The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit


WHO to take call on Covaxin's EUL on October 26th
News | October 18, 2021

WHO to take call on Covaxin's EUL on October 26th

The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17


U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Drug Approval | October 18, 2021

U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting


U.S. FDA advisory committee recommends J&J booster dose
Biotech | October 18, 2021

U.S. FDA advisory committee recommends J&J booster dose

U.S. FDA to decide whether to authorize a booster dose in the coming days


Exelixis in-licenses second anti-cancer compound from Aurigene
Biotech | October 15, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene

U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma


Expect normal quarter in Q2FY22: Emkay
News | October 15, 2021

Expect normal quarter in Q2FY22: Emkay

Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report


Hospitals to accelerate digital investments: Frost & Sullivan
Digitisation | October 14, 2021

Hospitals to accelerate digital investments: Frost & Sullivan

The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions


Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis
Biotech | October 14, 2021

Sputnik Light has 70 % efficacy against infection with Delta: Gamaleya analysis

Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations